CEMIP and laryngeal neoplasm: Through our experiments, we obtained many data, which provides a new evidence that KIAA1199 is highly expressed in primary LSCC tissues and its immunoreactivity is higher in cancerous than adjacent noncancerous tissues, revealing that KIAA1199 might help distinguish benign from malignant larynx tumors.